 |
|
|
| |
SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients:
Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study
|
| |
| |
Reported by Jules Levin
AASLD: The Liver Meeting® 2017, October 20-24, 2017, Washington, DC
Marc Bourliere,1 Stuart C. Gordon,2 Eugene R. Schiff,3 Tram T. Tran,4 Natarajan Ravendhran,5 Charles S. Landis,6 Robert H. Hyland,7 Jie Zhang,7 Hadas Dvory-Sobol,7 Luisa M. Stamm,7
Diana M. Brainard,7 John G. McHutchison,7 Lawrence Serfaty,8 Alex Thompson,9 Thomas E. Sepe,10 Michael P. Curry,11 K. Rajender Reddy,12 Michael P. Manns13
1Hôpital Saint Joseph, Marseille, France; 2Henry Ford Health System, Detroit, MI; 3University of Miami, Coral Gables, FL; 4Cedars-Sinai Medical Center, Los Angeles, CA; 5Digestive Disease Associates, Catonsville, MD; 6University of Washington, Seattle; 7Gilead Sciences, Inc., Foster City, CA;
8Hôpital Saint-Antoine, Paris, France; 9St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia; 10University Gastroenterology, Providence, RI; 11Beth Israel Deaconess Medical Center, Boston, MA; 12University of Pennsylvania, Philadelphia; 13Medizinischen Hochschule Hannover, Germany
*Acute myocardial infarction, grand mal seizure, hepatocellular cellular, mesenteric vein thrombosis, nephrolithiasis and urosepsis, thrombosis, and wrist fracture; Asymptomatic lipase elevations (n=9), creatinine kinase elevations associated with exercise (n=1), and glucose elevations in patients with medical history of diabetes or hyperglycemia (n=3), increased total bilirubin (n=2), and reduced lymphocyte counts (n=2).
References
1. Buggisch P, et al. EASL 2017, poster SAT-254; 2. Curry M, et al. N Engl J Med 2015;373:2618-28; 3. Curry MP, et al. EASL 2017, poster PS-102; 4. Feld J, et al. N Engl J Med 2015;373:2599-607; 5. Foster G,
et al. N Engl J Med 2015;373:2608-17; 6. Landis C, et al. AASLD 2017, abstr 1096; 7. Bourliere M, et al. N Engl J Med 2017;376:2134-46; 8. Jacobson IM, et al. Gastroenterology 2017;153:113-22.
|
| |
|
|
|
|
|
